PRMT5 and central nervous system cancer: PRMT5 activity is inhibited in MTAP-deficient glioma cells, which, in turn, downregulates the expression of E3 ubiquitin ligase SMURF2, leading to decreased stability of downstream histone H2AX and ultimately resulting in the genomic instability of tumor cells [14].